Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study

Show simple item record

dc.contributor.author McQueen, Fiona en
dc.contributor.author Lloyd, R en
dc.contributor.author Doyle, Anthony en
dc.contributor.author Robinson, Elizabeth en
dc.contributor.author Lobo, M en
dc.contributor.author Exeter, M en
dc.contributor.author Taylor, WJ en
dc.contributor.author Jones, Peter en
dc.contributor.author Reid, Ian en
dc.contributor.author Dalbeth, Nicola en
dc.date.accessioned 2012-03-06T20:52:58Z en
dc.date.issued 2011 en
dc.identifier.citation Ann Rheum Dis 70(6):1091-1094 Jun 2011 en
dc.identifier.issn 0003-4967 en
dc.identifier.uri http://hdl.handle.net/2292/13129 en
dc.description.abstract Background The effect of zoledronic acid (ZA) on articular bone in patients with psoriatic arthritis (PsA) was investigated using MRI.Methods Patients with erosive PsA were randomised to receive 3-monthly infusions of ZA or placebo for 1 year. An additional ‘tests alone’ group received no infusions. Clinical assessments and MRI scans were performed at baseline and 1 year.Results Paired 1.5T MRI scans were available in 22 patients including 6 who received ZA and 16 who did not (non-ZA = 6 placebo + 10 ‘tests alone’ patients). The Disease Activity Score (28 swollen and tender joints, C reactive protein fell over 12 months to a greater degree in patients on ZA than in non-ZA patients (−1.6 vs −0.3, p=0.023). The MRI bone oedema score decreased in the ZA group (15.5 to 8.5) but increased in the non-ZA group (14.0 to 18.0) (p= 0.0056) with regression of bone oedema at 13.5% of sites in ZA patients vs 1.3% in non-ZA patients (p = 0.0073) and progression in 1.3% of sites in ZA patients vs 6.9% in non-ZA patients (p = 0.072). There was no difference between groups in change in MRI erosion score.Conclusions In this pilot study ZA reduced the progression of MRI bone oedema, indicating probable suppression of osteitis concordant with reduction in clinical measures of disease activity. en
dc.language EN en
dc.relation.ispartofseries Annals of the Rheumatic Diseases en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0003-4967/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject JOINT DAMAGE en
dc.subject DESTRUCTION en
dc.subject PAMIDRONATE en
dc.subject ETANERCEPT en
dc.subject MARROW en
dc.title Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study en
dc.type Journal Article en
dc.identifier.doi 10.1136/ard.2010.142539 en
pubs.issue 6 en
pubs.begin-page 1091 en
pubs.volume 70 en
dc.rights.holder Copyright: BMJ Publishing Group Ltd. en
dc.identifier.pmid 21342915 en
pubs.author-url http://ard.bmj.com/content/70/6/1091.abstract en
pubs.end-page 1094 en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 198685 en
pubs.org-id Medical and Health Sciences en
pubs.org-id Medical Sciences en
pubs.org-id Anatomy and Medical Imaging en
pubs.org-id School of Medicine en
pubs.org-id Medicine Department en
pubs.org-id Science en
pubs.org-id Science Research en
pubs.org-id Maurice Wilkins Centre (2010-2014) en
pubs.record-created-at-source-date 2011-09-26 en
pubs.dimensions-id 21342915 en

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace